About
Vesalius Cardiovascular Inc. is a Preclinical Medical Device Company
We operate in the structural heart space and are developing a Transfemoral Mitral Valve Repair (TMVr) solution for a very common heart valve disease – Degenerative Mitral Regurgitation.
About Vesalius Cardiovascular Inc.
Our TMVr solution uses pre-established surgical techniques (transfemoral-transseptal delivery, annuloplasty, and chordal replacement). Our device reproduces these proven surgical results without the need to undergo surgery.
Our solution eliminates the burden associated with surgery and allows treatment to be available to almost all patients suffering from the underlying disease.
We are based in Vancouver, Canada.
Our Teams
The Management Team
Peter Skarsgard, MD
Chief Medical Officer
Dr. Skarsgard is a Cardiovascular Surgeon and Clinical Associate Professor of Surgery at the University of British Columbia, and Head of the Division of Cardiovascular Surgery at Vancouver General Hospital. His area of expertise is mitral valve repair and complex valvular surgery. Based upon a simple clinical observation, Dr. Skarsgard developed and patented concepts for devices aimed toward percutaneous treatment of mitral regurgitation, utilizing proven surgical principles. These ideas form the basis for Calla and Orion.
Vincent Ledoux, MSc
Chief Executive Officer
Mr. Ledoux is a Business Specialist with over 23 years experience in Investment Banking, Corporate Management and Startups. During his tenure at BNP Paribas, the largest bank in Europe, he successfully held several roles internationally and completed the prestigious General Inspection program within the group. Since 2009, he has been deeply involved in Canadian engineering and medical device startups. Vincent holds an MSc in Business Management from EMLyon Business School. Vincent manages the day-to-day activities and coordinates the R&D.
Ryan Harrington, MEng
Director of Engineering
Mr. Harrington is a Mechanical Engineer with over 8 years experience in engineering design and development, with a primary focus on cardiovascular implants. He was one of the first engineers to join Vesalius and grew with the company to lead the current team of 8 handpicked biomedical engineers. Ryan holds a Master of Engineering degree from University College Dublin in Ireland. He is responsible for all engineering aspects of the device development and regulatory affairs.
The Clinical Team
Dr. Robert Boone, MD
Interventional Cardiologist
Peter Skarsgard, MD
Chief Medical Officer
Dr. Skarsgard is a Cardiovascular Surgeon and Clinical Associate Professor of Surgery at the University of British Columbia, and Head of the Division of Cardiovascular Surgery at Vancouver General Hospital. His area of expertise is mitral valve repair and complex valvular surgery. Based upon a simple clinical observation, Dr. Skarsgard developed and patented concepts for devices aimed toward percutaneous treatment of mitral regurgitation, utilizing proven surgical principles. These ideas form the basis for Calla and Orion.
Dr. Christopher Durkin, MD
Anaesthesiologist/Echocardiographer
Dr. Durkin is a Clinical Assistant Professor of Anaesthesiology at the University of British Columbia, and a member of the Section of Cardiovascular Anaesthesiology at Vancouver General Hospital. In addition to expertise in cardiovascular physiology and pharmacology, he holds National Board of Echocardiography Certification in Advanced Perioperative Transesophageal Echocardiography, and is an expert in 3D echo for intracardiac structural disease and procedures. Dr. Durkin brings critical inputs in 3D echo imaging, both procedurally and in planning, to Vesalius Cardiovascular.
Vesalius Roadmap
-
2017
Start of engineering
-
2018
Start of in-vivo
-
2019
Start of QMS
-
2020
1st chronic in-vivo -
2021
1st FDA meeting -
2022
Frozen device
-
2023
GLP in-vivo study
-
2024
First-in-human approval